"Long‐Term Efficacy Of Brodalumab For The Treatment Of Moderate To Severe Psoriasis" — Mark G. Lebwohl, MD
Mark Lebwohl, MD, professor and chair of dermatology at the Icahn School of Medicine at Mount Sinai and system chair of the Waldman department of dermatology for the Mount Sinai Health System, speaks about the long term efficacy of brodalumab for the treatment of moderate to severe psoriasis. “There are several key findings from the study. First of all ‐ the drug is very fast, second of all ‐ it is very effective, and third of all ‐ the effect persists for up to 108 weeks in this study,” Dr. Lebwohl said.
- Mark Lebwohl, MD, Professor, Chair, Dermatology, Icahn School of Medicine at Mount Sinai, System Chair, Waldman Department of Dermatology, Mount Sinai Health System